

Application No. 09/701,500 - - - - 2

RECEIVED  
CENTRAL FAX CENTER

SEP 22 2003

Amendments to the Claims

OFFICIAL

1 (currently amended): An article of manufacture comprising packaging material and a pharmaceutical composition contained within said packaging material, wherein said pharmaceutical composition is capable of modulating angiogenesis in a tissue associated with a disease condition, wherein said packaging material comprises a label which indicates that said pharmaceutical composition can be used for treating disease conditions by modulating angiogenesis, and wherein said pharmaceutical composition comprises ~~a Src protein~~ or an oligonucleotide having a nucleotide sequence capable of expressing an active Src said protein.

2 (original): The article of manufacture of claim 1 wherein said Src protein is an active Src protein and said modulating potentiates angiogenesis.

3 (original): The article of manufacture of claim 2 wherein said active Src protein is Src A.

4 (original): The article of manufacture of claim 2 wherein said tissue has poor circulation.

5-11 (canceled).

12 (original): The article of manufacture of claim 1 wherein said administering comprises intravenous, transdermal, intrasynovial, intramuscular, or oral administration.

13 (original): The article of manufacture of claim 1 wherein said administering comprises a single dose intravenously.

14 (original): The article of manufacture of claim 1 wherein said pharmaceutical composition further comprises a liposome.

15 (original): The article of manufacture of claim 1 wherein said pharmaceutical composition comprises a viral expression vector capable of expressing said nucleotide sequence.

16 (original): The article of manufacture of claim 1 wherein said pharmaceutical composition comprises an non-viral expression vector capable of expressing said nucleotide sequence.

17-32 (canceled).

Application No. 09/704,500 - - - - 3

33 (currently amended): A pharmaceutical composition for stimulating angiogenesis in a target mammalian tissue comprising a viral gene transfer vector containing a nucleic acid and pharmaceutically acceptable carrier or excipient; said nucleic acid having a nucleic acid segment encoding for a src protein; said src protein having any amino acid residue at codon 527 except for tyrosine, serine or threonine.

34 (currently amended): A pharmaceutical composition for stimulating angiogenesis in a target mammalian tissue comprising a non-viral gene transfer vector containing a nucleic acid and pharmaceutically acceptable carrier or excipient; said nucleic acid having a nucleic acid segment encoding for a src protein and said src protein having any amino acid residue at codon 527 except tyrosine, serine or threonine.

35-38 (canceled).